Novo Nordisk’s ESSENCE trial of semaglutide 2.4 mg shows significant improvements in liver fibrosis and steatohepatitis outcomes, with regulatory filings planned for 2025.
read more Read More
Posted inBusiness & Finance
Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
